secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viking Therapeutics, Inc. (VKTX)
CIK:        0001607678
Form:       8-K
Filed at:   2023-06-14T23:59:59+00:00
Accession:  0000950170-23-027965
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viking Therapeutics shareholders reelect directors, ratify auditor, reject officer exculpation amendment
--------------------------------------------------------------------------------

- Elected J. Matthew Singleton and S. Kathy Rouan as Class II directors to serve until 2026 annual meeting.
- Ratified Marcum LLP as independent registered public accounting firm for FY2023 (76.6M for, 173k against).
- Advisory vote on named executive officer compensation passed (53.4M for, 1.3M against, 22.1M broker non-votes).
- Amendment to certificate of incorporation for officer exculpation under Delaware law failed; received 52.8M votes for (53% of outstanding), needed 66.7% of all shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1607678/000095017023027965/0000950170-23-027965-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1607678/000095017023027965/vktx-20230613.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-027965

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer